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Abstract
Background: It is unclear whether the gold standard 
test for the detection of partial clinical remission (PCR) 
in new-onset type 1 diabetes (T1D), the insulin-dose 
adjusted Hemoglobin A1c (IDAA1c) of ≤9, is superior to a 
new tool, total daily dose of insulin (TDD) of <0.3 units/
kg/day. The aim of the study was to test the superiority 
of IDAA1c over TDD of <0.3 units/kg/day for the detection 
of PCR.
Methods: A retrospective analysis of 204 subjects of ages 
2–14 years, mean age 7.9 ± 3.2 years, (male 7.8 ± 3.4 years, 
[n = 98]; female 7.9 ± 3.0  years, [n = 106], p = 0.816) with 
new-onset T1D. Anthropometric and biochemical data 
were collected for the first 36 months of disease. PCR was 
defined by both IDAA1c ≤ 9 and TDD < 0.3 units/kg/day.
Results: There were 86 (42.2%) (age 9.1 ± 3.0 years; male 
57%) remitters by IDAA1c ≤ 9 criterion, and 82 (40.2%) remit-
ters (age 7.3 ± 2.8 years) by TDD of <0.3 units/kg/day crite-
rion (p = 0.655). The duration of PCR was 10.0 ± 6.1 months 
using TDD < 0.3 units/kg/day, and 9.2 ± 5.5 months using 
IDAA1c (p = 0.379). Subjects in PCR as denoted by TDD < 0.3 
units/kg/day had 1.44 times increased probability of 
entering PCR than those denoted by IDAA1c of ≤9, after 
adjusting for BMI, bicarbonate, and HbA1c:(OR = 1.44, 95% 
CI [1.03–2.00], p = 0.033). Peak prevalence for PCR was 
at 6–12  months by either definition; more subjects were 
in PCR at 6  months by IDAA1c ≤9: 62/86 (72.1%) than by 
TDD < 0.3 units/kg/day: 43/82 (52.4%), (p = 0.011).
Conclusions: There were no significant differences in 
the  number of remitters, duration of PCR, or the time 
of peak remission defined by IDAA1c of ≤9 or TDD of 
<0.3 units/kg/day.
Keywords: bicarbonate; children and adolescents; hemo-
globin A1c; honeymoon period; insulin; type 1 diabetes.
Introduction
More than 50% of children and adolescents with new-
onset type 1 diabetes (T1D) will not experience partial 
clinical remission (PCR), also known as the honeymoon 
phase [1–4]. These non-remitters have been shown to have 
poorer short- and long-term diabetes outcome compared 
to those who entered PCR [5–8]. A recent long-term study 
found a significantly reduced risk for chronic microvas-
cular complications at 7-year follow-up in patients who 
entered PCR [9]. Thus, patients who undergo PCR, also 
known as remitters, have an overall prognostic advantage 
over non-remitters, but there is no consensus on a simple 
and easily usable tool for the detection and monitoring of 
PCR in children and adolescents.
The IDAA1c, which integrates HbA1c and total daily 
dose (TDD), is considered the gold standard for detec-
tion of PCR, and its validation in multiple cohort studies 
[10, 11] is helpful for the characterization of PCR in clini-
cal studies. Despite its strength as a surrogate marker 
of serum C-peptide, IDAA1c has been criticized for its 
various shortcomings; for example, age, a major determi-
nant of PCR, is not included in its formula [12]. Addition-
ally, IDAA1c underestimates PCR in younger children with 
new-onset T1D who often have lower serum C-peptide 
levels; because it was optimized using a higher C-peptide 
cut-off value of 300 pmol/L, instead of the 200 pmol/L 
validated by the Diabetes Control and Complications 
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Trial [12, 13]. IDAA1c also underestimates the prevalence 
of PCR in older girls who are more insulin resistant, since 
IDAA1c cannot discriminate between insulin sensitiv-
ity and insulin secretion [13]. Cengiz et  al. [13] recently 
reported that IDAA1c was not a sensitive measure of the 
risk for severe hypoglycemia in patients with newly diag-
nosed T1D. IDAA1c was derived from a cohort of European 
and Japanese subjects, who may have different diabe-
tes characteristics from the general US population [13]. 
Finally, although the components are readily accessible, 
calculating the IDAA1c may represent a barrier to time-
strapped clinicians, a factor that prevents widespread 
use. In a recent multi-center study, Nagl et al. [11] called 
for additional research to clarify the usefulness and per-
formance of IDAA1c in clinical practice, with an emphasis 
on determining age- and sex-specific IDAA1c limits for the 
definition of PCR based on the serial determination of 
serum C-peptide concentration.
IDAA1c has been extensively compared to previous 
definitions of PCR [1, 3, 12, 14–19], such as HbA1c ≤ 7.5%, 
TDD of insulin ≤0.5 units/kg/day [14], or a combination of 
HbA1c ≤ 7.5% and TDD ≤ 0.5 units/kg/day [19]. IDAA1c was 
found to be less sensitive than TDD < 0.5 units/kg/day for 
the early detection of PCR following the diagnosis of T1D, 
but was more specific for PCR between 6 and 12 months 
[12]. These comparisons further showed that IDAA1c has 
a stronger correlation with stimulated C-peptide concen-
tration than previous definitions [12]; and that the use of 
either TDD of ≤0.5 units/kg/day, or HbA1c of <7.5% could 
overestimate the prevalence of PCR; while the use of a 
combination of TDD of ≤0.5 units/kg/day and HbA1c of 
<7.5% could underestimate PCR [12].
However, IDAA1c has not been compared to TDD of 
insulin <0.3 units/kg/day, which is another sensitive tool 
for the detection of PCR [20]. It has been hypothesized that 
TDD of <0.3 units/kg/day may fall in an intermediate posi-
tion between TDD of ≤0.5 units/kg/day [14] and the com-
bination of HbA1c of <7.5% and TDD of ≤0.5 units/kg/day 
[19]. Furthermore, the calculation of TDD is already being 
performed by endocrinologists during routine clinic visits. 
Therefore, in a busy outpatient clinic, TDD of <0.3 units/
kg/day may serve as a more practical tool for early detec-
tion and monitoring of PCR in children and adolescents 
with new-onset T1D than the IDAA1c.
We designed this study to investigate whether IDAA1c 
of ≤9 is superior to TDD < 0.3 units/kg/day in detecting 
PCR in children and adolescents with new-onset T1D. We 
hypothesized that there would be no significant difference 
in the number of remitters identified by either definition, 
suggesting TDD < 0.3 may be an adequate test for PCR for 
clinical use.
Subjects and methods
Ethics statement
This study protocol was approved by the Institutional Review 
Board of the University of Massachusetts. All subjects’ records were 
anonymized and de-identified prior to analysis.
Subjects
Study subjects were pediatric patients of ages 2–14  years with a 
confirmed diagnosis of T1D from January 1, 2006 through Septem-
ber 30, 2015 from the Children’s Medical Center Database of the 
UMass Memorial Medical Center, Worcester, MA, USA. As detailed 
in Nwosu and Maranda [21], the diagnosis of T1D was established 
using any of the following glycemic parameters: a fasting blood 
glucose of ≥7  mmol/L (126  mg/dL), and/or 2-h postprandial glu-
cose of ≥11.1 mmol/L (200 mg/dL), and/or random blood glucose of 
≥11.1 mmol/L (200 mg/dL) with symptoms of polyuria and/or poly-
dipsia. In addition, all participants were positive for one or more 
diabetes-associated auto-antibodies, namely insulin autoantibodies, 
islet cell cytoplasmic autoantibodies, glutamic acid decarboxylase 
antibodies, and/or insulinoma-associated-2 (IA-2A) autoantibodies. 
Subjects with other forms of diabetes mellitus were excluded from 
the study.
Following the diagnosis of diabetes mellitus, all patients had 
blood drawn for routine diagnostic testing to confirm the diagnosis 
of T1D and to assess for acidosis. Patients that were not in diabetic 
ketoacidosis (DKA) were started on a standard basal-bolus insulin 
regimen, consisting of injections of once-daily long-acting insulin 
and pre-meal short-acting insulin. Patients in DKA were started on 
an insulin drip at 0.05 units/kg/h, which was titrated to maintain gly-
cemia until the resolution of acidosis. All patients were discharged 
from the hospital on a basal-bolus insulin regimen.
Ongoing data collection for anthropometric, clinical (HbA1c, 
TDD of insulin), and biochemical parameters were conducted 
at baseline (at diagnosis), every 3  months for the first year, and 
every 3–6  months until 36  months. Missing data were accounted 
for in the statistical analysis using linear mixed models. DKA was 
defined by pH < 7.35, blood glucose >200 mg/dL, and serum bicar-
bonate <15  ng/mL [22]. PCR was defined by both a TDD of <0.3 
units/kg/day, and by the gold-standard methodology, IDAA1c ≤ 9 
[10, 12]. The formula for IDAA1c is HbA1c (%) +(4 X TDD of insulin 
[units/kg/24 h]).
Anthropometry
As described in detail previously [23, 24], weight was measured to 
the nearest 0.1 kg using an upright scale. Height was measured to 
the nearest 0.1 cm using a wall-mounted stadiometer that was cali-
brated daily. BMI was calculated from the formula: weight/height2 
(kg/m2), and expressed as standard deviation score (SDS) for age 
and sex, based on National Center for Health Statistics (NCHS) 
data [25]. Overweight was defined as BMI of ≥85th but <95th per-
centile, and obesity was defined as BMI of ≥95th percentile for age 
and gender.
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Assays
Assays for laboratory chemistries have been previously described 
[23, 24]. Briefly, serum 25(OH)D concentration was analyzed using 
25-hydroxy chemiluminescent immunoassay (DiaSorin Liaison; Still-
water, MN, USA), which measures total serum 25(OH)D content by 
detecting both metabolites of 25(OH)D: 25(OH)D2 and 25(OH)D3. It has 
intra- and inter-assay coefficients of variation of 5% and 8.2%, respec-
tively, and a functional sensitivity of 10 nmol/L. Hemoglobin A1c was 
measured by DCA 2000 +  Analyzer (Bayer, Inc., Tarrytown, NY, USA) 
based on Diabetes Control and Complications Trial standards [26]. 
Serum bicarbonate was measured at the University of Massachusetts 
Medical School Clinical Laboratory by total carbon dioxide (CO2) esti-
mation using Beckman Coulter AU system CO2 reagent according to 
the method of Forrester et al. [27]. Diabetes-associated autoantibod-
ies were measured by Quest Diagnostics, Chantilly, VA, USA. GAD-65 
assay was performed using enzyme-linked immunosorbent assay, 
and IA-2A and IAA assays were performed using radio-binding assay.
Statistical analyses
Means and standard deviations (SD) were calculated for descriptive 
summary statistics and biochemical parameters. Linear mixed mod-
els were used to compare the means of continuous covariates between 
the remitters and non-remitters. Student’s t-test was used to make the 
comparison between the groups for non-anthropometric continuous 
variables namely, TDD of insulin, and HbA1c [13]; and Fisher exact test 
was used for categorical variables. These variables were compared 
using both definitions for PCR (IDAA1c of ≤9 and TDD < 0.3 units/kg/
day). Cox’s proportional hazard models were used to investigate the 
adjusted associations between the duration of remission and covari-
ates of interest. The duration of PCR was calculated as the interval 
between the first and last documented time points with IDAA1c value 
of ≤9. The analysis was performed using SPSS Predictive Analytics 
Software v.23 (IBM Corporation, Armonk, NY, USA).
Results
Baseline analysis
Anthropometry
Two hundred and four children and adolescents, ages 
2–14  years with a mean age of 7.9 ± 3.2  years, (male 
7.8 ± 3.4 years, [n = 98]; female 7.9 ± 3.0 [n = 106], p = 0.816) 
with new-onset T1D were analyzed. When PCR was 
defined by a TDD insulin <0.3 units/kg/day, there were 
82 remitters (age 7.3 ± 2.8 years, male 50%) and 123 non-
remitters (age 8.2 ± 3.4 years, male 53.7%). The prevalence 
of remission was 40.2%, with the peak period of remission 
occurring between 6 and 12 months (Table 1).
When PCR was defined by IDDA1c ≤ 9, there were 
86 remitters (age 9.1 ± 3.0  years, male 57%), and 118 
non-remitters (age 7.0 ± 3.1 years; male 40.7%). The preva-
lence of remission using IDAA1c was 42.2%, and the peak 
period of remission was between 6 and 12 months.
A sub-analysis of the two groups that focused on 
direct comparison of the remitters as designated by IDAA1c 
vs. TDD < 0.3 units/kg/day showed that subjects in remis-
sion as defined by TDD insulin <0.3 units/kg/day were 
younger (p < 0.001), and required a lower TDD of insulin at 
baseline (p = 0.006), and at 6 months (p = 0.02) (Table 1). 
Table 2 shows that hemoglobin A1c values were lower at 6, 
9, and 24 months in subjects in whom PCR was defined by 
IDDA1c ≤ 9.
At baseline, remitters were significantly younger 
than non-remitters by the TDD < 0.3 units/kg/day cri-
terion, (7.3 ± 2.8 vs. 8.2 ± 3.4  years, p = 0.038), but were 
significantly older than the non-remitters by the IDAA1c 
criterion (9.1 ± 3.0 vs. 7.0 ± 3.1 years, p < 0.001). Height SDS 
was similar at baseline between the remitters and non-
remitters by either the TDD < 0.3 units/kg/day criterion, 
(0.2 ± 0.8 vs. 0.3 ± 1.1, p = 0.797) or the IDAA1c criterion 
(0.2 ± 1.0 vs. 0.3 ± 1.0, p = 0.348). Weight SDS was signifi-
cantly lower in the remitters at 24  months by TDD < 0.3 
units/kg/day criterion (0.3 ± 0.9 vs. 0.7 ± 1.0, p = 0.02) but 
was similar between remitters and non-remitters through-
out the study by IDAA1c criterion (0.5 ± 0.9 vs. 0.7 ± 0.8, 
p = 0.412).
BMI-SDS was significantly lower in remitters at 
24 months (0.4 ± 0.8 vs. 0.7 ± 0.9, p = 0.032) and 36 months 
(0.4 ± 0.9 vs. 0.9 ± 0.7, p = 0.040) by TDD < 0.3 units/kg/day 
criterion, but was similar from diagnosis through 36 months 
by IDAA1c criterion (0.6 ± 0.9 vs. 0.6 ± 0.9, p = 0.593).
Biochemical parameters
Serum bicarbonate (HCO3) was significantly higher in 
remitters than in non-remitters using IDAA1c criterion; a 
trend that was also present, although non-significant, 
using TDD < 0.3 units/kg/day. Using the HbA1c-defined 
IDAA1c to identify PCR, HbA1c was significantly lower in 
the first 3–18  months of disease in remitters; HbA1c was 
significantly lower only at 3 months of disease using the 
TDD < 0.3 units/kg/day definition of PCR (Table 1, Figure 1). 
Serum 25(OH)D concentration was similar between the 
remitters and non-remitters by either criterion.
Time and duration of PCR
The mean duration of PCR was 10.0 ± 6.1  months using 
TDD < 0.3 units/kg/day, compared to 9.2 ± 5.5  months 
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Table 1: Comparison of the anthropometric and biochemical characteristics of (A) remitters and non-remitters, and (B) remitters only, 
by using both insulin dose-adjusted hemoglobin A1c of ≤9 and total daily dose of <0.3 units/kg/day to define partial clinical remission in 
patients with new-onset type 1 diabetes.
Definition of PCR  
 
IDAA1c ≤ 9 
 
TDD < 0.3 units/kg/day  p-Value 
comparing 
remitters onlyParameter Remitters (n = 86)
  Non-remitters 
(n = 118)
  p-Value Remitters 
(n = 82)
  Non-remitters 
(n = 123)
  p-Value
Age, years   9.1 ± 3.0  7.0 ± 3.1  <0.001  7.3 ± 2.8  8.2 ± 3.4  0.038  <0.001
Age (categorized)       <0.001      0.15  0.002
 0–4 years   9 (11%)  36 (31%)    21 (26%)  24 (20%)   
 5–10 years   38 (44%)  58 (49%)    42 (51%)  55 (44%)   
 11–14 years   39 (45%)  24 (20%)    19 (23%)  44 (36%)   
Sex
Male   49 (57%)  48 (41%)  0.02  41 (50%)  57 (46%)  0.61  0.36
Female   37 (43%)  70 (59%)    41 (50%)  66 (54%)   
Height SDSa   0.2 ± 1.0  0.3 ± 1.0  0.35  0.2 ± 0.8  0.3 ± 1.1  0.80  0.89
Weight SDSa   0.5 ± 1.0  0.4 ± 0.9  0.59  0.6 ± 0.8  0.4 ± 1.0  0.04  0.88
BMI-SDSa   0.6 ± 1.0  0.5 ± 1.0  0.14  0.6 ± 0.9  0.4 ± 1.1  0.009  0.52
25-hydroxyvitamin D, nmol/L   67.5 ± 28.4  66.1 ± 19.4  0.72  69.1 ± 26.5  65.2 ± 21.4  0.32  0.75
HCO3 at diagnosis, mmol/L   21.4 ± 5.9  18.3 ± 8.3  0.006  20.7 ± 6.9  18.8 ± 7.9  0.09  0.58
Duration of PCR, months   9.2 ± 5.5  0.1 ± 1.1  <0.001  10.0 ± 6.1  0.0 ± 0.0  <0.001  0.379
TDD at diagnosis, units/kg/day   0.5 ± 0.3  0.5 ± 0.2  0.33  0.4 ± 0.2  0.6 ± 0.2  <0.001  0.006
TDD at 6 months   0.3 ± 0.2  0.5 ± 0.2  <0.001  0.2 ± 0.2  0.6 ± 0.2  <0.001  0.02
TDD at 18 months   0.5 ± 0.2  0.7 ± 0.2  <0.001  0.5 ± 0.2  0.7 ± 0.2  <0.001  0.10
TDD at 24 months   0.5 ± 0.3  0.7 ± 0.3  <0.001  0.6 ± 0.2  0.7 ± 0.3  <0.001  0.71
TDD at 36 months   0.7 ± 0.3  0.8 ± 0.3  0.17  0.7 ± 0.3  0.8 ± 0.3  0.44  0.68
IDAA1c, insulin-dose adjusted hemoglobin A1c; TDD, total daily dose; SDS, standard deviation score; BMI, body mass index; 25(OH)D, 
25 hydroxyvitamin D; HCO3, bicarbonate. aComparison made by Linear mixed model adjusting for sex and age. For this study, partial clinical 
remission (PCR) was defined by both TDD of <0.3 units/kg/day; and also by IDAA1c, a two-dimensional definition that correlates insulin dose 
and measured HbA1c to residual β-cell function [10]. IDAA1c has the best agreement with stimulated C-peptide definition of >300 pmol/L when 
compared to previous definitions [12]. The formula for IDAA1c is: HbA1c (%) +[4 X insulin dose (units/kg/24 h)]. PCR was defined as IDAA1c of 
≤9 [10]. Significant p-values are bolded.
Table 2: Comparison of the hemoglobin A1c values of (A) remitters and non-remitters, and (B) remitters only, by using both insulin dose-
adjusted hemoglobin A1c of ≤9 and total daily dose of <0.3 units/kg/day to define partial clinical remission in patients with new-onset type 1 
diabetes.
Definition of PCR  
 
IDAA1c ≤ 9 
 
TDD < 0.3 units/kg/day  p-Value 
comparing 
remitters onlyParameter Remitters (n = 86)
  Non-remitters 
(n = 118)
  p-Value Remitters 
(n = 82)
  Non-remitters 
(n = 123)
  p-Value
HbA1c (%) at diagnosis  11.4 ± 2.4  11.5 ± 2.1  0.58  10.8 ± 2.2  11.9 ± 2.2  0.001  0.09
HbA1c at 3 months   7.5 ± 1.0  8.6 ± 1.3  <0.001  7.8 ± 1.3  8.3 ± 1.3  0.015  0.10
HbA1c at 6 months   7.3 ± 1.3  8.8 ± 1.3  <0.001  7.9 ± 1.2  8.3 ± 1.7  0.06  0.002
HbA1c at 9 months   7.8 ± 1.0  8.7 ± 1.0  <0.001  8.1 ± 0.9  8.4 ± 1.2  0.08  0.04
HbA1c at 12 months   7.9 ± 1.1  8.7 ± 1.0  <0.001  8.2 ± 1.0  8.5 ± 1.2  0.06  0.07
HbA1c at 15 months   8.1 ± 1.0  8.7 ± 0.9  <0.001  8.3 ± 1.0  8.5 ± 1.0  0.18  0.20
HbA1c at 18 months   8.2 ± 1.1  8.7 ± 1.2  0.008  8.5 ± 1.0  8.6 ± 1.3  0.71  0.07
HbA1c at 21 months   8.4 ± 1.0  8.8 ± 1.1  0.09  8.5 ± 1.0  8.7 ± 1.2  0.31  0.52
HbA1c at 24 months   8.5 ± 1.1  8.8 ± 0.9  0.07  8.9 ± 1.1  8.6 ± 0.9  0.09  0.02
HbA1c at 27 months   8.5 ± 1.2   8.5 ± 1.4   0.82  8.6 ± 0.9  8.5 ± 1.5  0.79  0.54
HbA1c at 30 months   8.5 ± 1.1  8.8 ± 1.0  0.13  8.5 ± 1.0  8.7 ± 1.1  0.39  1.00
HbA1c at 33 months   8.7 ± 1.4   8.6 ± 1.0  0.72  8.6 ± 1.0  8.7 ± 1.2  0.64  0.59
HbA1c at 36 months   8.4 ± 1.2  8.8 ± 1.0  0.09  8.6 ± 1.2  8.7 ± 1.0  0.68  0.25
IDAA1c, insulin-dose adjusted hemoglobin A1c; HbA1c, hemoglobin A1c. Significant p-values are bolded.
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using IDAA1c of ≤9 (p = 0.379). Peak prevalence for PCR 
occurred at 6–12 months and the proportion of patients in 
PCR at 6 months was 43/82 (52.4%) using TDD < 0.3 units/
kg/day; and 62/86 (72.1%) using IDAA1c ≤ 9 (p = 0.011).
Logistic regression analysis, adjusted for baseline 
BMI-SDS, HbA1c, and serum bicarbonate, was performed 
to determine the likelihood of subjects entering PCR using 
either IDAA1c ≤ 9 and TDD < 0.3 units/kg/day to define 
PCR. HbA1c adjustment was necessary because the HbA1c 
level at diagnosis is a reflection of the pre-diagnostic gly-
cemia and initial insulin therapy, which could affect the 
validity of the definitions for PCR [12].
The results showed that among the remitters, those 
diagnosed using TDD < 0.3 units/kg/day criterion were 
1.44 times more likely to enter honeymoon in the first 
4 months than those diagnosed with IDAA1c criterion, after 
adjusting for BMI-SDS, serum bicarbonate, and baseline 
HbA1c:(OR = 1.44, 95% CI [1.03–2.00], p = 0.033) (Figure 2).
Discussion
This is the first study to compare the gold standard formula 
for the detection of PCR detection, IDAA1c, to TDD < 0.3 
units/kg/day to determine the accuracy of TDD < 0.3 units/
kg/day to correctly identify patients in PCR. The results 
of this study, in a US population, showed that a similar 
proportion of patients entered PCR using either IDAA1c or 
TDD < 0.3 units/kg/day: 42.2% vs. 40.2%, respectively. Our 
findings are consistent with earlier reports of the occurrence 
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Figure 1: Graphical representation of the patterns of hemoglobin A1c (HbA1c) trends in remitters and non-remitters in the first 36 months fol-
lowing the diagnosis of type 1 diabetes using either IDAA1c of ≤9 [10] (left panel) or TDD of <0.3 units/kg/day (right panel) to define PCR.
Using TDD of <0.3 units/kg/day to define PCR, mean HbA1c level was significantly was lower in the remitters at diagnosis (10.8 ± 2.2 vs. 
11.9 ± 2.2, p = 0.001), and at 3 months (7.8 ± 1.3 vs. 8.3 ± 1.3, p = 0.015), compared to the non-remitters, but remained non-significantly lower 
until the 15th month after diagnosis, when the mean HbA1c values became similar between the groups. Using the IDAA1c of ≤9 criterion, mean 
HbA1c was similar at diagnosis between the remitters and non-remitters (11.4 ± 2.4 vs. 11.5 ± 2.1%, p = 0.584), then became significantly 
lower in the remitters from 3 months (7.5 ± 1.0 vs. 8.6 ± 1.3%, p < 0.001), through 18 months (8.2 ± 1.1 vs. 8.7 ± 1.2%, p = 0.008), and was 
non-significantly lower in the remitters thereafter.
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Figure 2: Kaplan-Meier survival curve showing the time to entering 
partial clinical remission (PCR) over time.
Only remitters are shown; the graph depicts the decay in sur-
vival without remission over time, comparing the two remission 
definitions. Remitters diagnosed using the TDD < 0.3 units/kg/day 
criterion were 1.44 times more likely to enter honeymoon in the first 
4 months of disease than those diagnosed with IDAA1c criterion, 
after adjusting for confounders (OR = 1.44, 95% CI [1.03–2.00], 
p = 0.033).
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of PCR in 40%–70% of children diagnosed with new-onset 
T1D [11, 28]. Both definitions identified the peak prevalence 
of patients in remission between 6 and 12 months, with a 
majority of patients in remission at 6 months. Kaplan-Meier 
survival analysis showed an earlier detection of PCR by 
TDD < 0.3  units/kg/day, and a slightly increased probabil-
ity of early remission by this definition compared to IDAA1c. 
However, there was a significantly higher proportion of 
patients in remission at 6 months by IDAA1c criterion com-
pared to TDD < 0.3 units/kg/day. These findings are consist-
ent with previous reports showing that the use of TDD alone 
as a definition of PCR identifies patients in remission sooner 
than IDAA1c, possibly due to the practice of starting patients 
on a relatively lower TDD of insulin at diagnosis [3, 12].
The report that >50% of children and adolescents 
with new-onset T1D do not experience PCR [1–4], and that 
these non-remitters have increased risk for both the short- 
and long-term diabetes complications [5–8] is of major 
concern. The recent report of a long-term study which 
found a significantly reduced risk for chronic microvas-
cular complications at 7-year follow-up in patients who 
entered PCR [9] suggests that the primary mechanism for 
the endothelial dysfunction and vascular disease in non-
remitters may be related to persistent hyperglycemia in the 
early phase of T1D. This is supported by recent findings 
suggesting that the underlying mechanism for the vascu-
lar damage in T1D is oxidative stress induced by several 
hyperglycemia-activated pathways such as the activated 
polyol and hexosamine pathways, activation of protein 
kinase C, increased production of advanced glycation 
end-products, and excessive production of growth factors, 
angiotensin II, and cytokines [29]. Both acute and chronic 
hyperglycemia work in concert to produce these compli-
cations as chronic hyperglycemia is reported to promote 
the onset and progression of microvascular complications 
[30], while acute hyperglycemia accelerates the progres-
sion of these complications [29]. This hyperglycemic effect 
is partly explained by the ‘hyperglycemic memory’ phe-
nomenon, which proposes that prompt correction of dys-
glycemia in the early phase of T1D decreases the risk of 
its long-term complications [9]. Taken together, remitters 
have an overall prognostic advantage over non-remitters. 
Therefore, the introduction of a simpler definition for PCR 
such as TTD < 0.3 units/kg/day will enable early identi-
fication of non-remitters and the institution of targeted 
therapeutic regimens to prevent early dysglycemia in chil-
dren and adolescents with T1D.
The limitations of this study include the fact that 
this was a retrospective cross-sectional study and thus 
no causality should be inferred from the relationships 
between the parameters studied. The lack of data on 
serum C-peptide limited our ability to test the reliability 
of the definition of PCR based on either IDAA1c or TDD 
in this population. This study did not compare a combi-
nation of TDD of <0.3 units/kg/day plus HbA1c of <7.5% 
to IDAA1c because the aim of the study was to develop a 
simple, straightforward formula for an accurate detec-
tion of PCR. Equally, prior studies had shown that the 
combination of TDD < 0.5 units/kg/day with HbA1c < 7.5% 
lacked sensitivity. However, a cross-sectional analysis of 
our dataset at 6 months after the diagnosis of T1D showed 
that when PCR was defined by a combination of TDD < 0.3 
units/kg/day and HbA1c of <7.5%, only 14.6% of subjects 
were in remission, and 41.7% of the patients were classi-
fied as false negatives. This underestimation of PCR by a 
combination of TDD < 0.3 units/kg/day and HbA1c of <7.5% 
is similar to previously described underestimation of PCR 
by a combination of TDD of ≤0.5 units/kg/day and HbA1c 
of <7.5% [12]. The high false-negative rates result from 
the exclusion of individuals who enter PCR as defined by 
IDAA1c and TDD < 0.3 units/kg/day but still have elevated 
HbA1c levels, especially in the early phase of the disease 
when HbA1c is still dropping from the elevated values at 
diagnosis. The detection and monitoring accuracy of 
TDD < 0.3 units/kg/day could be improved by combining 
it with an automatic, blood glucose-driven insulin dose 
adjustment algorithm that removes provider bias while 
ensuring early normalization of HbA1c value. Strengths 
of this study include the use of a representative sample 
size, and extending data collection for up to 36 months. 
There was an adequate representation of age groups, sex, 
race, and current BMI status in this US cohort to allow for 
meaningful comparison between the remitters and non-
remitters using either definition under study.
Conclusions
This study found no significant differences in the number 
of remitters, duration of PCR, or the time of peak remis-
sion detected by either IDAA1c of ≤9 or TDD of <0.3 units/
kg/day. TDD of <0.3 units/kg/day detected PCR earlier 
than IDAA1c, while IDAA1c detected a higher proportion of 
remitters at 6 months. Thus, TDD of <0.3 units/kg/day was 
not inferior to IDAA1c for the detection of PCR and may be 
a simpler, user-friendly tool for routine clinical practice, 
while the IDAA1c will continue to be used for research 
purposes.
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